US 9309250
Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
granted A61PA61P35/00A61P35/02
Quick answer
US patent 9309250 (Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors) held by Vertex Pharmaceuticals Incorporated expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Vertex Pharmaceuticals Incorporated
- Grant date
- Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 40
- CPC classes
- A61P, A61P35/00, A61P35/02, A61P43/00